Monopar Therapeutics Inc (MNPR) USD0.001

Sell:$27.00Buy:$42.90$0.13 (0.42%)

Prices delayed by at least 15 minutes
Sell:$27.00
Buy:$42.90
Change:$0.13 (0.42%)
Deal now
Prices delayed by at least 15 minutes
Sell:$27.00
Buy:$42.90
Change:$0.13 (0.42%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Key people

Christopher M. Starr
Executive Chairman of the Board
Chandler D. Robinson
Chief Executive Officer, Director
Vu Quan
Chief Financial Officer, Principal Accounting Officer
Andrew J. Cittadine
Chief Operating Officer
Patrice P. Rioux
Acting Chief Medical Officer
Kim R. Tsuchimoto
Director
Raymond William Anderson
Independent Director
Arthur J. Klausner
Independent Director
Lavina Talukdar
Independent Director
Click to see more

Key facts

  • EPIC
    MNPR
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US61023L2079
  • Market cap
    $193.45m
  • Employees
    10
  • Shares in issue
    6.10m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.